B4GALNT3

Across TCGA pan-cancer cohorts, B4GALNT3 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated B4GALNT3 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher B4GALNT3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated B4GALNT3 expression acts as an unfavorable survival marker, although some lineages such as COAD and UCEC show a favorable association.

HNSC, OV, and KIRP are the cancer types where B4GALNT3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.061	0.645	<.001	36	view →
OV	OS	Median	All	0.244	0.690	.006	18	view →
KIRP	OS	Median	II,III,IV	0.188	0.771	.016	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	DFS	Median	II,III,IV	1.000	0.746	.030	4	view →
GBM	DFS	Median	All	0.065	0.244	.005	3	view →
LIHC	OS	Median	All	0.105	0.774	.002	3	view →
UCEC	DFS	Median	All	0.933	0.626	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

B4GALNT3–HNSC (DFS)

Open the HNSC breakdown →